Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT06395116 Active, not recruiting - Clinical trials for Inflammatory Response

Microbial Adhesion and Biofilm Formation on Denture Base Materials

Start date: January 20, 2023
Phase:
Study type: Observational

Polymethylmethacrylate (PMMA) has been the material of choice for fabricating complete dentures for more than 80 years now.(1,2) As a material it is easy to handle and can be easily repaired and polished. PMMA while being a low-cost material has good esthetics. Some disadvantages of PMMA as a material are surface roughness and porosities which lead to staining, plaque accumulation and bacterial adhesion over time. Among the various factors that can influence microbial attachment to surfaces, surface roughness, hydrophilicity and free surface energy of PMMA are most important. Carboxylate and methyl ester groups found in PMMA make it a very hydrophilic material with a large amount of free surface energy. Despite the influence of the chemical composition, processing methods play the most important role in developing surface roughness.

NCT ID: NCT06394518 Completed - Clinical trials for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

Start date: July 7, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.

NCT ID: NCT06393387 Not yet recruiting - HIV Infections Clinical Trials

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

Start date: June 1, 2024
Phase:
Study type: Observational

This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States

NCT ID: NCT06392568 Recruiting - Critical Illness Clinical Trials

Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units

NOSOREA3
Start date: April 1, 2024
Phase:
Study type: Observational

Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.

NCT ID: NCT06392451 Not yet recruiting - Clinical trials for Coronavirus Disease 2019

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

Start date: May 6, 2024
Phase: N/A
Study type: Interventional

To establish the relative accuracy of the LIAISON® NES Flu A/B, RSV & COVID-19 assay for viral nucleic acid targets from professionally collected or patient self-collected dry nasal (NS) swabs and to establish the relative accuracy of the LIAISON PLEX® RSP Flex assay from NS and nasopharyngeal swabs (NPS) in applicable transport media from human patients exhibiting clinical signs and symptoms of a respiratory tract infection.

NCT ID: NCT06392282 Active, not recruiting - Clinical trials for Urinary Tract Infections

MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients

Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

We will access the efficacy of MV-140 immunotherapy in the prevention of recurrent urinary tract infections in a cohort of Portuguese patients.

NCT ID: NCT06390878 Recruiting - Atopic Dermatitis Clinical Trials

Nationwide Research on the Rewilding of Kindergarten Yards

Vahvistu
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities that is associated with altered commensal microbiota and a rising burden of immunological disorders among urban children. The investigators will estimate how rewilding of kindergarten yards affects commensal microbiome, prevalence of allergies, asthma, atopic dermatitis and infections, cortisol levels, cognitive skills and plasma cytokine levels of children. Our specific aims are: To assess if rewilding diversifies health-associated skin, saliva and gut microbiota and reduces infectious diseases and atopic or allergic symptoms. Assess whether the rewilding has positive effects on cognitive skills. Assess whether the rewilding changes cortisol and plasma cytokine levels. The investigators will recruit altogether 320 (160 per treatment) study subjects aged between 1-5 to questionnaire study (Task 2), from which 120 study subjects will be analyzed more detailed using microbiological and blood samples (Task 1).

NCT ID: NCT06390696 Recruiting - Atopic Dermatitis Clinical Trials

Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis

BIWE
Start date: May 26, 2023
Phase: N/A
Study type: Interventional

The prevalence of atopic dermatitis has increased along with urbanization and biodiversity loss. According to biodiversity hypothesis, the main reason is urban lifestyle and reduced contact to microbial diversity. Previous studies indicate association between atopic dermatitis and exposure to natural microbes in childhood. Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis will investigate whether the exposure to microbial diversity in sandbox reduces the symptoms of atopic dermatitis, alters commensal microbiota and modifies immune regulation in children.

NCT ID: NCT06390683 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Biodiversity Interventions for Assisted Living Centers

BIWE
Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Biodiversity is essential for nature and human well-being. Land use has reduced biodiversity in cities, which weakens the functionality of the urban ecosystems and the well-being of citizens. This may also increase the risk of immune-mediated disorders among urban dwellers. In Biodiversity interventions for assisted living centers (BIWE 2), microbial biodiversity interventions are performed to increase biodiversity in urban housing units for people with autism spectrum disorder, disabled people and elderly. Results from the intervention trials are combined with publicly available land cover and ecological data. These are analyzed from the viewpoint of shifts in ecosystems and human well-being and immune regulation, ecological quality, and urban planning. The investigators set up an intervention study in which yards of the housing units are rewilded with diverse vegetation and decaying deadwood and plant residuals. The investigators aim to evaluate the effect of rewilding, and yard management practices on commensal microbiome, cortisol levels and well-being and salivary cytokine levels, and gene pathways.

NCT ID: NCT06389383 Active, not recruiting - Newborn; Infection Clinical Trials

Pilot Study - Monitoring the Nasal Microbiome and Viral Respiratory Infections in Newborn Hospitalized in Neonatalogy.

NEONATMICROBIO
Start date: December 21, 2022
Phase: N/A
Study type: Interventional

The objective of our study is therefore to study the evolution of the respiratory microbiome of hospitalized newborns, its interaction with viral infections and their impacts on the evolution of newborns.